Journal Article

Modulation of tumor formation and intestinal cell migration by estrogens in the <i>Apc</i><sup><i>Min</i>/+</sup> mouse model of colorectal cancer

Sara H. Javid, Amy E. Moran, Adelaide M. Carothers, Mark Redston and Monica M. Bertagnolli

in Carcinogenesis

Volume 26, issue 3, pages 587-595
Published in print March 2005 | ISSN: 0143-3334
Published online March 2005 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/bgh346
Modulation of tumor formation and intestinal cell migration by estrogens in the ApcMin/+ mouse model of colorectal cancer

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Epidemiological studies suggest that post-menopausal hormone replacement therapy (HRT) reduces colorectal cancer (CRC) incidence. Phytoestrogens, including the soy isoflavone genistein and coumestrol, are used by many women as alternatives to HRT. Previous studies showed that ovariectomy induced a 77% increase in intestinal adenoma number in the C57BL/6J-Min/+ (Min/+) mouse, an animal model of adenomatous polyposis coli (APC)-associated CRC. Replacement of estradiol (E2) in ovariectomized Min/+ mice reduced tumor number to baseline and up-regulated the expression of estrogen receptor β (ERβ). We hypothesized that the phytoestrogens genistein and coumestrol would inhibit intestinal tumorigenesis in ovariectomized Min/+ mice. Min/+ and Apc+/+ (WT) mice were ovariectomized and assigned to either a control diet or treatment with E2, genistein or coumestrol. Treatment of ovariectomized Min/+ (Min/+ OX) mice with genistein resulted in a non-significant reduction in tumor number. Min/+ OX mice treated with coumestrol had significantly fewer tumors than untreated Min/+ OX controls and the same number of tumors as non-ovariectomized Min/+ mice. Bromodeoxyuridine migration assays also demonstrated that treatment with E2 or coumestrol improved enterocyte migration rate. Immunoprecipitation and immunohistochemistry analyses showed that impaired association of the adherens junction proteins E-cadherin and β-catenin in Min/+ mice was improved by treatment with either E2 or coumestrol. Immunoblot analyses also showed that expression of ERβ was elevated in enterocytes of Min/+ OX mice treated with E2 or coumestrol as compared with those of untreated Min/+ OX mice. In conclusion, both coumestrol and E2 prevent intestinal tumorigenesis and ameliorate enterocyte migration and intercellular adhesion in the ApcMin/+ mouse model of CRC.

Keywords: AJ, adherens junction; ALLN, N-acetyl-Leu-Leu-norleucinal; APC, adenomatous polyposis coli; BrdU, 5-bromodeoxyuridine; CRC, colorectal cancer; E2, 17β-estradiol; ER, estrogen receptor; FAP, familial adenomatous polyposis; HRT, hormone replacement therapy; IB, immunoblot; IHC, immunohistochemistry; IP, immunoprecipitation; Min/+, C57Bl6/J-ApcMin/+; Min/+ OX, ovariectomized Min/+; PAO, phenylarsine oxide; PMSF, phenylmethylsulfonyl fluoride; TCL, total cell lysate; WHI, Women's Health Initiative; WT, wild-type; WT OX, ovariectomized WT

Journal Article.  7002 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.